Hikma Pharma
A range trading opportunity for you?
Will Hikma break support, or will it rise again back to 2000p?
- The Hikma range has developed since late August, bolstered by rising support.
- Bounced off support zone 5 times, and 5 times off rising support .
- Currently trading 1706p (at time of writing)
- Will the pattern repeat itself, testing previous highs?
- Shares -18.4% from 2018 highs; +109.4% from 2018 lows; +50.7% since end-17.
- 2 Dec: Hikma plants sold to Investor Group
- 19 Dec: Hikma replaces Shire in UK 100
- 19 Nov: Hikma launches Triazolam Tablets
- 8 Nov: Panmure says Hikma is sensible partner for Vectura’s respiratory ambitions:
- Source: Bloomberg, FT, Reuters, DJ Newswires, AlphaTerminal
Trading Hikma – An Example
Let’s say you like the range, you think it’s heading back towards 2000p again. You decide to buy exposure to £10,000 worth of Hikma using a CFD, at the current price of 1706p. To do this, you need £2,000.
Let’s assume Hikma recovers back to 2000p (+17.2%). Your profit would be £1720, from your initial investment of £2,000.
Conversely, let’s assume you open the above position, and place a stop-loss at 5% from the current price. Hikma falls 5% and hits your stop-loss. Your loss would be £500.
This is provided for information purposes only. It should not be taken as a recommendation.